Total body cooling or selective head cooling is a management option that has shown to improve neurodevelopment outcomes for infants with which condition?

Total body cooling or selective head cooling is a management option that has shown to improve neurodevelopment outcomes for infants with which condition?

• A. Hypoxic-Ischemic Encephalopathy
• B. Neonatal meningitis
• C. Respiratory distress syndrome
• D. Neonatal abstinence syndrome

Answer: (A)

Therapeutic hypothermia, whether total body cooling or selective head cooling, is used after a perinatal hypoxic-ischemic event to limit secondary brain injury. In term or near-term infants with hypoxic-ischemic encephalopathy, initiating cooling within a few hours of birth and continuing for about 72 hours lowers brain metabolic demand, reduces excitotoxic injury, dampens inflammatory processes, and limits cell death. This neuroprotection has been demonstrated in major trials to improve neurodevelopmental outcomes, decreasing the risk of death or moderate to severe disability by 18–24 months. The approach is typically offered to infants with evidence of perinatal asphyxia and abnormal neurological status, with careful monitoring due to possible side effects like bradycardia, coagulopathy, electrolyte disturbances, and infection risk. The other conditions listed—meningitis, respiratory distress syndrome, and neonatal abstinence syndrome—have different underlying mechanisms and standard treatments, and cooling has not been shown to reliably improve long-term neurodevelopment for those conditions, so it is not used as a routine neuroprotective strategy for them.

Therapeutic hypothermia, whether total body cooling or selective head cooling, is used after a perinatal hypoxic-ischemic event to limit secondary brain injury. In term or near-term infants with hypoxic-ischemic encephalopathy, initiating cooling within a few hours of birth and continuing for about 72 hours lowers brain metabolic demand, reduces excitotoxic injury, dampens inflammatory processes, and limits cell death. This neuroprotection has been demonstrated in major trials to improve neurodevelopmental outcomes, decreasing the risk of death or moderate to severe disability by 18–24 months. The approach is typically offered to infants with evidence of perinatal asphyxia and abnormal neurological status, with careful monitoring due to possible side effects like bradycardia, coagulopathy, electrolyte disturbances, and infection risk. The other conditions listed—meningitis, respiratory distress syndrome, and neonatal abstinence syndrome—have different underlying mechanisms and standard treatments, and cooling has not been shown to reliably improve long-term neurodevelopment for those conditions, so it is not used as a routine neuroprotective strategy for them.